Novo Nordisk taps Microsoft's AI to boost drug discovery

Novo Nordisk taps Microsoft's AI to boost drug discovery

Source: Fierce BiotechBy Andrea Park

Artificial intelligence has increasingly become a go-to tool—rather than a novelty—for drugmakers looking to build the next generation of groundbreaking therapeutics.

Big Pharmas around the world are forging partnerships to apply AI technology to their drug discovery and development processes, including Novo Nordisk, which announced Monday that it has inked a deal with Microsoft to speed up its drug discovery work.

The collaboration will span several years and will see Microsoft lend its AI and other cloud-based data analytics tools to Novo’s R&D department. The companies said they’re planning to take a “platform approach” in their tech partnership, meaning that they’ll develop broad AI models that they can adapt and apply to a wide variety of tasks as time goes on.

Keep reading...